Haisco and Lilly Sign Collaboration and Licensing Deals
What’s happening
A unit of China's Haisco Pharmaceutical entered collaboration and licensing agreements with Eli Lilly and Company involving experimental medicines.
The agreements give Lilly access to additional drug-development opportunities while helping Haisco expand the global reach of its research programs.
What’s changing / Business impact
Large pharmaceutical companies increasingly rely on partnerships rather than developing every drug internally.
These agreements allow companies to share risk, speed up development, and gain access to promising technologies.
Why this matters
Modern drug development has become extremely expensive and complex. Partnerships help companies access innovation wherever it is being created, regardless of geography.
This trend has become a major feature of the pharmaceutical industry.